In advanced NSCLC without EGFR or ALK aberrations, immunotherapy alone is the standard treatment in second line and, in PDL-1 strong positive (tumor proportion score > 50%) tumors, in first line [1]. This evidence concerns the gene CD274 and neoplasm.